Neurological drug developer Rodin Therapeutics has now raised more than $57m in total, its past investors including Johnson and Johnson and Biogen.
GV, the corporate venturing unit formerly known as Google Ventures, contributed to a $27m funding round for US-based neurological disorder drug developer Rodin Therapeutics that closed on Monday.
Venture capital firms Atlas Venture, Hatteras Venture Partners and Remeditex Ventures also participated in the round, along with Third Point Ventures, the VC arm of hedge fund Third Point Management.
Rodin is developing small-molecule therapeutics that will treat neurological disorders like Alzheimer’s disease and Parkinson’s disease by enhancing a patient’s synaptic resilience.
…
